

AMENDMENTS TO THE CLAIMS

1-23. (Canceled).

24. (Currently Amended) A method for reducing eosinophil[[ia]] recruitment into the lung in a human comprising administering to the human a compound comprising a modified oligonucleotide having 8 to 50 consisting of 12 to 50 linked nucleosides that is targeted to the sequence of intercellular adhesion molecule-1 (ICAM-1) having SEQ ID NO:138, wherein said modified oligonucleotide is at least 90% complementary to SEQ ID NO:138 as measured over the entirety of said modified oligonucleotide, wherein said compound is administered into the lung, and wherein said modified oligonucleotide inhibits expression of intercellular adhesion molecule-1 (ICAM-1) and reduces eosinophil[[ia]] recruitment into the lung in the human.

25. (Canceled).

26. (Currently Amended) The method of claim 24, wherein the modified oligonucleotide ~~has~~ consists of 15 to 30 linked nucleosides.

27. (Currently Amended) The method of claim ~~25~~ or 26 ~~24~~, wherein the modified oligonucleotide consists of 20 linked nucleosides.

28. (Currently Amended) The method of claim 27, wherein the modified oligonucleotide ~~is has~~ a nucleotide sequence consisting of SEQ ID NO: 22.

29. (Currently Amended) The method of claim 24, wherein reducing eosinophil[[ia]] recruitment into the lung ameliorates an inflammatory condition.

30. (Previously Presented) The method of claim 24, wherein the modified oligonucleotide is co-administered with a steroidal anti-inflammatory agent.

31-32. (Canceled).

33. (Previously Presented) The method of claim 24, wherein the modified oligonucleotide is a single-stranded oligonucleotide.

34. (Currently Amended) The method of claim 24, wherein the modified oligonucleotide is 100% complementary to SEQ ID NO: 138 as measured over the entirety of said modified oligonucleotide.

35. (Previously Presented) The method of claim 24, wherein at least one internucleoside linkage is a modified internucleoside linkage.

36. (Previously Presented) The method of claim 35, wherein at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage.

37. (Previously Presented) The method of claim 24, wherein at least one nucleoside comprises a modified sugar.

38. (Previously Presented) The method of claim 37, wherein at least one modified sugar is a bicyclic sugar.

39. (Previously Presented) The method of claim 37, wherein at least one modified sugar comprises a 2'-O-methoxyethyl.

40. (Previously Presented) The method of claim 24, wherein at least one nucleoside comprises a modified nucleobase.

41. (Previously Presented) The method of claim 40, wherein the modified nucleobase is a 5-methylcytosine.

42. (Previously Presented) The method of claim 24, wherein the modified oligonucleotide comprises:

- a. a gap segment consisting of linked deoxynucleosides;
- b. a 5' wing segment consisting of linked nucleosides; and
- c. a 3' wing segment consisting of linked nucleosides,

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

43. (Canceled).

44. (New) The method of claim 24, wherein the modified oligonucleotide comprises:  
a gap segment consisting of ten linked deoxynucleosides;  
a 5' wing segment consisting of five linked nucleosides; and  
a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; wherein each cytosine in said modified oligonucleotide is a 5-methylcytosine, and wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate linkage.

**Application No.:** 10/559401  
**Filing Date:** September 11, 2008

45. (New) The method of claim 44, wherein the modified oligonucleotide consists of 20 linked nucleosides.